Cure­Vac re­leas­es mixed in­ter­im Phase 2 da­ta for sea­son­al flu vac­cine

Cure­Vac’s sea­son­al flu vac­cine boost­ed an­ti­body titers in in­fluen­za A strains but it missed the mark in in­fluen­za B in a Phase 2 tri­al.

The mR­NA biotech, which is de­vel­op­ing the vac­cine with GSK, on Thurs­day an­nounced the in­ter­im da­ta from the on­go­ing tri­al. Its stock $CVAC was up about 1.5%, trad­ing at $2.95.

Cure­Vac said the titers gen­er­at­ed by its vac­cine can­di­date ex­ceed­ed the titers from the com­par­i­son vac­cine against in­fluen­za A strains across all dose lev­els.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER